Results 201 to 210 of about 3,679,356 (272)

Correction to "Better Response and Prognosis of Venetoclax Plus Hypomethylating Agents Over Intensive Chemotherapy in Young Adults With Newly Diagnosed ASXL1-Mutated Acute Myeloid Leukemia". [PDF]

Cancer Med
europepmc   +1 more source

Correction: Efficacy and prognostic analysis of venetoclax combined with hypomethylating agents for induction therapy in acute myeloid leukemia: a multi-center real-world study on indication-specific stratification, molecular markers, and hematologic toxicities. [PDF]

Cancer Cell Int
Xia L, Qu M, Ge L, Chen Y, Zhou B, Shi T, Liu Y, Ruan M, Xia L, Hong J, Li J, Qian W, Zhang Y, Jiang L, Zhao Y, Tian W, Huang Z, Jin F, Ge J, Yang M, Zeng Q.   +20 more
europepmc   +1 more source

Does the Timing of Response Impact the Outcome of Relapsed/Refractory Acute Myeloid Leukemia Treated with Venetoclax in Combination with Hypomethylating Agents? A Proof of Concept from a Monocentric Observational Study. [PDF]

J Clin Med
Longo E, Palumbo FE, Duminuco A, Longo L, Vitale DC, Brancati S, Maugeri C, Parisi MS, Palumbo GA, Romano GL, Drago F, Di Raimondo F, Gozzo L, Vetro C.   +13 more
europepmc   +1 more source

Longer time from diagnosis to initiation of hypomethylating agents plus venetoclax for acute myeloid leukemia does not worsen survival: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). [PDF]

Haematologica
Yates SJ, Weiss JJ, Sneider A, Geramita E, Murthy GSG, Badar T, Im A, Lin C, Cheng W, Abaza Y, Swaroop A, Winer ES, Litzow MR, Atallah EL, Patel AA, Shallis RM.   +15 more
europepmc   +1 more source

Significant prognostic improvement in elderly patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax: outcomes from a retrospective real-world analysis. [PDF]

Ann Med
Chen Y, Wang Z, Cai R, Wu Z, Zhou J, Wu L, Wu Y, Zheng J.   +7 more
europepmc   +1 more source

Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in NPM1-mutant AML. [PDF]

Blood Adv
Bewersdorf JP, Shimony S, Shallis RM, Liu Y, Berton G, Schaefer EJ, Zeidan AM, Goldberg AD, Stein EM, Marcucci G, Bystrom RP, Lindsley RC, Chen EC, Ramos Perez J, Stein A, Pullarkat V, Aldoss I, DeAngelo DJ, Neuberg DS, Stone RM, Garciaz S, Ball B, Stahl M.   +22 more
europepmc   +1 more source

Prognostic value of measurable residual disease (MRD) for venetoclax in combination with hypomethylating agents in patients diagnosed with acute myeloid leukemia: validation of the ELN-2021 MRD recommendations. [PDF]

Blood Cancer J
Jimenez-Vicente C, Cardus A, Castaño-Diez S, Ramil G, Garcia-Avila S, Gomez-Perez L, Esteban D, Arribas I, Sturla AL, Lopez-Guerra M, Martinez-Roca A, Cortes-Bullich A, Perez-Valencia AI, Zugasti I, Monge I, Carcelero E, Vall-Llovera F, Vives S, Sierra J, Nomdedeu J, Oñate G, Garrido A, Pratcorona M, Pomares H, Arnan M, Guijarro F, Diaz-Beya M, Esteve J, Spanish CETLAM Group.   +28 more
europepmc   +1 more source

Integrating advanced analytical methods to assess epigenetic marks affecting response to hypomethylating agents in higher risk myelodysplastic syndrome. [PDF]

Mol Med
Nikolopoulos T, Bochalis E, Chatzilygeroudi T, Chondrou V, Dereki I, Athanasopoulou K, Zafeiropoulos J, Bourikas K, Patrinos GP, Symeonidis A, Sgourou A.   +10 more
europepmc   +1 more source

A novel prognostic risk model for patients with refractory/relapsed acute myeloid leukemia receiving venetoclax plus hypomethylating agents. [PDF]

Leukemia
Shahswar R, Gabdoulline R, Krueger K, Wichmann M, Götze KS, Braitsch K, Meggendorfer M, Schmalbrock L, Bullinger L, Modemann F, Fiedler W, Krauter J, Kaun S, Rotermund S, Voß A, Behrens YL, Bergmann AK, Koller E, Beutel G, Thol F, Heidel F, Heuser M.   +21 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial.

The Lancet Haematology, 2023
BACKGROUND Sabatolimab is an immunotherapy targeting T-cell immunoglobulin domain and mucin domain-3 (TIM-3), an immuno-myeloid regulator expressed on immune cells and leukaemic stem cells.
A. Zeidan, Kiyoshi Ando, O. Rauzy, Mehmet Turgut, Ming-Chung Wang, R. Cairoli, H. Hou, Y. Kwong, Montserrat Arnan, Stefaan Meers, V. Pullarkat, V. Santini, K. Malek, F. Kiertsman, J. Niolat, Pedro Marques Ramos, Hans-Dietrich Menssen, Pierre Fenaux, Yasushi Miyazaki, U. Platzbecker   +19 more
semanticscholar   +1 more source